Physicians' Biological Drug Preference in Patients With Rheumatoid Arthritis and Spondyloarthritis With a History of Malignancy: Perspectives From the Treasure Database. Issue 2 (20th March 2022)

• Record Type: Journal Article
• Authors: Tekgoz, Emre; Colak, Seda; Yardimci, Kubra G.; Kucuksahin, Orhan; Cinar, Muhammet; Yilmaz, Sedat; Kasifoglu, Timucin; Bes, Cemal; Yagiz, Burcu; Erden, Abdulsamet; Kilic, Levent; Kanitez, Nilufer A.; Ertenli, Ali I.; Coskun, Belkis N.; Ediboglu, Elif D.; Mercan, Ridvan; Kiraz, Sedat; Yazisiz, Veli; Karadag, Omer; Atagunduz, Pamir; Kalyoncu, Umut
• Is Part Of: Journal of clinical rheumatology. Volume 28:Issue 2(2022)
• Page Start: e318
• Page End: e323
• Publication Date: 2022-03-20
• Subjects: biological disease-modifying antirheumatic drugs -- malignancy -- rheumatoid arthritis -- spondyloarthritis; Rheumatism -- Periodicals; Rheumatology -- Periodicals; Musculoskeletal system -- Diseases -- Periodicals; Musculoskeletal Diseases -- Periodicals; Rheumatic Diseases -- Periodicals; Rhumatisme -- Périodiques; Rhumatologie -- Périodiques; Appareil locomoteur -- Maladies -- Périodiques; Musculoskeletal system -- Diseases; Rheumatism; Rheumatology; Periodicals; 616.723005
• DOI: 10.1097/RHU.0000000000001699
• Languages: English
• ISSNs: 1076-1608

Abstract

Abstract : Objective: Because of concerns about malignancy risks, using biological disease-modifying antirheumatic drugs (bDMARDs) in patients with a history of malignancy remains a challenging issue in rheumatology practice. This study aimed to investigate bDMARD preferences of physicians when treating of rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients with a history of malignancy. Methods: The data for this cross-sectional study were gathered from the TReasure database using a date range of December 2017 and January 2020. Biological disease-modifying antirheumatic drug preferences were analyzed for 40 RA patients and 25 SpA patients with a history of malignancy. Results: The most frequently prescribed bDMARD was rituximab, which was given to 28 RA patients (70%). For 25 patients (62.5%), the time between the diagnosis of malignancy and starting on a bDMARD regimen was less than 60 months, with a median interval of 43.5 months. Among SpA patients, the preferred bDMARDs were secukinumab and etanercept, which were each administered to 7 patients (28%). For 13 SpA patients (52%), the time between the diagnosis of malignancy and starting on bDMARDs was less than 60 months, with a median interval of 97 months. Conclusions: The observed bDMARD preferences may be related to the therapeutic effects of rituximab on lymphoproliferative malignancies, the protective effects of secukinumab on tumor progression, and the short half-life of etanercept. Biological disease-modifying antirheumatic drugs should be used in RA and SpA patients with malignancy in case of high inflammatory activity.